Insider Transactions in Q4 2020 at Vir Biotechnology, Inc. (VIR)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+22.25%
|
$9,500
$1.53 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.19 P/Share
|
|
Dec 22
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$117,955
$31.27 P/Share
|
|
Dec 08
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$215,295
$31.53 P/Share
|
|
Dec 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,930
-11.0%
|
$87,900
$30.0 P/Share
|
|
Nov 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,930
+9.91%
|
$2,930
$1.53 P/Share
|
|
Nov 27
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+11.58%
|
$0
$0.86 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-8.99%
|
$63,180
$27.29 P/Share
|
|
Nov 24
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|
|
Nov 12
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+28.66%
|
$0
$0.86 P/Share
|
|
Nov 10
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
2,340
-8.99%
|
$60,840
$26.26 P/Share
|
|
Nov 10
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|
|
Nov 04
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.57%
|
$5,000
$1.53 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$215,264
$31.27 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$133,175
$35.04 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,500
-15.5%
|
$595,000
$34.15 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+9.32%
|
$25,000
$2.76 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-19.0%
|
$239,080
$43.03 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+15.97%
|
$5,560
$1.53 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-16.06%
|
$512,500
$41.74 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+12.75%
|
$12,500
$1.55 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$236,130
$34.75 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|